Published in Women's Health Weekly, August 28th, 2003
The study is composed of 120 mice in 8 groups. Mice are excellent herpes disease models because they die within a few weeks after infection if left untreated. Preliminary results are expected within 30 days.
"These trials will demonstrate safety and pharmacologic effectiveness prior to human studies. In addition, we are testing our formulation for use as a prophylactic (preventative) as well as a therapeutic for long term cure," stated Dr. Malcolm Skolnick, CytoGenix's president/CEO.
"Existing herpes treatments do...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly